The incidence of cytomegalovirus infection in lung transplant recipients under universal prophylaxis with intravenous ganciclovir

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 2, 2007, Pages 212-214

  Schröeder, Regina ^a   Michelon, Tatiana ^a   Wurdig, João ^a,b   Fagundes, Iara ^a   Schio, Sadi ^a   Sanchez, Leticia ^a   Camargo, José J ^a   Sukkienik, Teresa C ^a   Pasqualotto, Alessandro C ^a,c   Neumann, Jorge ^a  

^a Santa Casa Complexo Hospitalar   (Brazil)

^b UNIVERSIDADE DO VALE DO RIO DOS SINOS   (Brazil)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antigenemia; Cytomegalovirus; Ganciclovir; Lung transplantation; Prophylaxis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; VIRUS DETECTION;

EID: 34547110781     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702007000200008     Document Type: Article

References (23)

1. Duncan A.J., Dummer J.S., Paradis I.L., et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991;10:638-44.
2. Ettinger N.A., Bailey T.C., Trulock E.P., et al. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147:1017-23.
3. Limaye A.P. Ganciclovir-resistant cytornegalovirus in organ transplant recipients. Clin Infect Dis 2002;35:866-72.
4. Limaye A.P., Raghu G., Koelle D.M., et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185:20-7.
5. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7.
6. Gane E., Saliba F., Valdecasas G.J., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997; 350:1729-33.
7. Lowance D.; Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462-70.
8. Limaye A.P., Corey L., Koelle D.M., et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645-9.
9. Fishman J.A., Doran MT, Volpicelli S.A., et al. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection. in solid organ transplant recipients. Transplantation 2000;69:389-94.
10. Razonable R.R., Rivero A., Rodriguez A., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001;184:1461-4.
11. Gerbase M.W., Dubois D., Rothmeier C., et al. Cost and outcome of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest 1999; 116:1265-72.
12. Hertz M.I., Jordan C., Savik S.K., et al. Randomized trial of daily versus three-times-weekly prophylactic ganeiclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998; 17:913-20.
13. Emery V.C. Prophylaxis for CNW should not now replace pretemptive therapy in solid organ transplantation. Rev Med Virol 2001; 11:83-6.
14. Emery V.C, Griffiths P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000;97:8039-44.
15. Schroeder R., Michelon T., Fagundes I., et al. Antigenemia, for cytomegalovirus in post renal transplantation: choosing a cut off for the diagnosis criteria in cytomegalovirus disease. Transplant Proc 2005;37:2781-3.
16. Schroeder R., Mesko J., Santos A., et al. Cytomegalovirus antigenemia and renal function post-kidney-transplantation. Transplant Proc 1999;31:3027-8.
17. Schroeder R., Michelon T., Fagundes I., et al. Comparison between RFLP-PCR and antigenemia for pp65 antigen for diagnosis of cytomegalovirus after kidney transplantation. Transplant Proc 2004;36:891-3.
18. Schroeder R., Michelon T., Fagundes I., et al. Cytomegalovirus disease latent and active infection rates during the first trimester after kidney transplantation. Transplant Proc 2004;36:896-8.
19. Zamora M.R., Davis R.D., Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005;80:157-63.
20. Egan J.J., Lomax J., Barber L., et al. Preemptive treatment for the prevention of cytomegalovirus disease: In lung and heart transplant recipients. Transplantation 1998;65:747-52.
21. Gerna G, Baldanti F., Lilleri D., et al. Human cytornegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: A prospective, randomized, controlled, open-label trial. Transplantation 2003;75:1012-9.
22. Kelly J., Hurley D., Raghu G. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant 2000;19:355-9.
23. Perreas K.Cx, McNeil K., Charman S., et al. Extended. ganciclovir prophylaxis in lung transplantation. J Heart Lung Transplant 2005; 24:585-7.